PMID- 37747620
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20231116
IS  - 1179-1896 (Electronic)
IS  - 1175-5652 (Linking)
VI  - 21
IP  - 6
DP  - 2023 Nov
TI  - Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for 
      Cancer: A Systematic Review.
PG  - 841-855
LID - 10.1007/s40258-023-00833-5 [doi]
AB  - INTRODUCTION: There is a boom in imaging biomarker-driven companion and 
      complementary diagnostics (CDx) for cancer, which brings opportunity for 
      personalized medicine. Whether adoption of these technologies is likely to be 
      cost-effective is a relevant question, and studies on this topic are emerging. 
      Despite the growing number of economic evaluations, no review of the methods 
      used, quality of reporting, and potential risk of bias has been done. We report a 
      systematic review to identify, summarize, and critique the cost-effectiveness 
      evidence for the use of biomarker-driven and imaging-based CDx to inform cancer 
      treatments. METHODS: The Preferred Reporting Items of Systematic Reviews and 
      Meta-Analyses (PRISMA) guidelines were followed. Systematic literature searches 
      until 30 December 2022 were performed in PubMed, Web of Science, Medline, Embase, 
      and Scopus for economic evaluations of imaging biomarker-based CDx for cancer. 
      The inclusion and exclusion of studies were determined by pre-specified 
      eligibility criteria informed by the 'Patient, Intervention, Comparison, Outcome' 
      (PICO) framework. The Consolidated Health Economic Evaluation Reporting Standards 
      (CHEERS) was used to assess the quality of reporting, and the Bias in Economic 
      Evaluation (ECOBIAS) was used to examine the potential risk of bias of included 
      studies. RESULTS: A total of 12 papers were included, with eight model-based and 
      four trial-based studies. Implementing biomarker-driven, imaging-based CDx was 
      reported to be cost-effective, cost saving, or dominant (cost saving and more 
      effective) in ten papers. Inconsistent methods were found in the studies, and the 
      quality of reporting was lacking against the CHEERS reporting guideline. Several 
      potential sources of 'risk of bias' were identified. These should be acknowledged 
      and carefully considered by researchers planning future health economic 
      evaluations. CONCLUSION: Despite favorable results towards the implementation of 
      imaging biomarker-based CDx for cancer, there is room for improvement regarding 
      the quantity and quality of economic evaluations, and that is expected as 
      the awareness of current study limitations increases and more clinical data 
      become available in the future.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Liu, Sibo
AU  - Liu S
AUID- ORCID: 0009-0007-9850-319X
AD  - Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, 
      Singapore, 169857, Singapore.
FAU - Tan, Daniel Sw
AU  - Tan DS
AUID- ORCID: 0000-0002-6514-6786
AD  - Cancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 30 
      Hospital Boulevard, Singapore, 168853, Singapore.
FAU - Graves, Nicholas
AU  - Graves N
AUID- ORCID: 0000-0002-5559-3267
AD  - Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, 
      Singapore, 169857, Singapore. n.graves@duke-nus.edu.sg.
FAU - Chacko, Ann-Marie
AU  - Chacko AM
AUID- ORCID: 0000-0001-5140-2622
AD  - Division of Cellular and Molecular Research, National Cancer Centre Singapore, 30 
      Hospital Boulevard, Singapore, 168853, Singapore. 
      ann-marie.chacko@duke-nus.edu.sg.
AD  - Laboratory for Translational and Molecular Imaging, Programme in Cancer & Stem 
      Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore, 169857, 
      Singapore. ann-marie.chacko@duke-nus.edu.sg.
LA  - eng
GR  - H18/01/a0/018/Agency for Science, Technology and Research/
GR  - Phase 2 Research Block Grant/Duke-NUS Medical School/
PT  - Systematic Review
DEP - 20230925
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
SB  - IM
MH  - Humans
MH  - Cost-Benefit Analysis
MH  - *Neoplasms/diagnostic imaging
EDAT- 2023/09/25 12:41
MHDA- 2023/11/07 06:46
CRDT- 2023/09/25 11:13
PHST- 2023/09/07 00:00 [accepted]
PHST- 2023/11/07 06:46 [medline]
PHST- 2023/09/25 12:41 [pubmed]
PHST- 2023/09/25 11:13 [entrez]
AID - 10.1007/s40258-023-00833-5 [pii]
AID - 10.1007/s40258-023-00833-5 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2023 Nov;21(6):841-855. doi: 
      10.1007/s40258-023-00833-5. Epub 2023 Sep 25.